Palvella Therapeutics, Inc. $PVLA Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its holdings in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 688.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,907 shares of the company’s stock after purchasing an additional 15,637 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Palvella Therapeutics were worth $2,232,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of PVLA. KBC Group NV purchased a new position in Palvella Therapeutics during the 1st quarter worth $28,000. Group One Trading LLC raised its holdings in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at about $36,000. JPMorgan Chase & Co. boosted its stake in shares of Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after buying an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Palvella Therapeutics during the second quarter worth about $85,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Stock Up 1.8%

Shares of Palvella Therapeutics stock opened at $157.77 on Friday. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -32.66 and a beta of -0.17. Palvella Therapeutics, Inc. has a 52-week low of $38.95 and a 52-week high of $161.38. The company’s 50-day simple moving average is $133.76 and its 200-day simple moving average is $120.02.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Equities research analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the transaction, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Chardan Capital upgraded Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Truist Financial set a $207.00 price objective on Palvella Therapeutics in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Palvella Therapeutics has an average rating of “Buy” and a consensus target price of $209.14.

Trending Headlines about Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Investor focus is on the potential approval of QTORIN, Palvella’s lead product candidate. Approval could provide a path to commercialization and future revenue growth, supporting the bullish outlook ahead of the regulatory decision. Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $270 price target, implying substantial upside from recent trading levels. Its projections anticipate a transition from losses to positive earnings beginning in 2029, with EPS forecast at $6.18 in 2029 and $19.10 in 2030.
• Neutral Sentiment: The latest analysis questions whether PVLA is already fully valued ahead of the QTORIN approval decision. With the stock near its 52-week high and a market capitalization of approximately $2.27 billion, further gains may depend heavily on a favorable regulatory outcome and successful commercialization.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across multiple periods: 2026 to a loss of $6.79 per share, 2027 to a loss of $7.43, and 2028 to a loss of $0.83. The firm also lowered its 2029 forecast from $7.81 to $6.18 and its 2030 forecast from $21.72 to $19.10.
• Negative Sentiment: Near-term quarterly estimates were also cut, with projected losses of $1.98 per share for the third quarter of 2026 and $2.05 for the fourth quarter. The revisions reinforce that Palvella remains an unprofitable biotechnology company and may require continued funding before reaching profitability. Palvella Therapeutics analyst estimates

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.